Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience

R A Hajjeh; L Privor-Dumm; K Edmond; R O'Loughlin; S Shetty; U K Griffiths; A P Bear; A L Cohen; A Chandran; A Schuchat; E K Mulholland; M Santosham

doi:10.1016/j.vaccine.2010.07.028

Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience

Vaccine. 2010 Oct 8;28(43):7123-9. doi: 10.1016/j.vaccine.2010.07.028. Epub 2010 Jul 24.

Authors

R A Hajjeh¹, L Privor-Dumm, K Edmond, R O'Loughlin, S Shetty, U K Griffiths, A P Bear, A L Cohen, A Chandran, A Schuchat, E K Mulholland, M Santosham

Affiliation

¹ Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-25, Atlanta, GA 30333, USA. RHajjeh@cdc.gov, rfh5@cdc.gov

PMID: 20659515
DOI: 10.1016/j.vaccine.2010.07.028

Abstract

The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

MeSH terms

Bacterial Capsules / administration & dosage*
Developing Countries
Haemophilus Infections / prevention & control*
Haemophilus Vaccines / administration & dosage*
Humans
Immunization Programs / organization & administration*
Public-Private Sector Partnerships

Substances

Haemophilus Vaccines
Haemophilus influenzae type b polysaccharide vaccine